Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

Bill Maher hits Huberman with a simple question: “What are peptides?” The answer unfolds into something much bigger. Peptides are short chains of amino acids our bodies produce naturally — insulin is one, GLP-1 is another. Now we’re synthesizing advanced versions like retatrutide, a triple agonist (GLP-1 + GIP...

newstart_2024's profile picture

Camus

460,962 subscribers

452,262 Aufrufe • vor 6 Monaten •via X (Twitter)

Gesundheit & WellnessNachrichten & PolitikWissenschaft & Technologie
LIVE

Anya Rossi• Live Now

Private livecam show

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

Andrew Huberman just broke down the next wave of weight-loss drugs on Gwyneth Paltrow’s goop podcast. He says the new triple agonist Retatrutide (currently in trials) is a big step up from Ozempic and Mounjaro. It hits three pathways (GLP-1 + glucagon + GIP) more gently, leading to significant weight loss with potentially less muscle loss and fewer side effects. People are already hunting for gray/black market versions. Early trial data on Retatrutide showed participants losing up to 24% of their body weight over 48 weeks, with notably better muscle preservation compared to earlier GLP-1 drugs when combined with resistance training. These next-generation drugs are becoming more targeted, but access, safety, and proper use remain key issues. This conversation made the rapid evolution of these drugs feel very real. It’s wild how fast this space is moving. What’s your take on the new generation of GLP drugs like Retatrutide?
3:32

Andrew Huberman just broke down the next wave of weight-loss drugs on Gwyneth Paltrow’s goop podcast. He says the new triple agonist Retatrutide (currently in trials) is a big step up from Ozempic and Mounjaro. It hits three pathways (GLP-1 + glucagon + GIP) more gently, leading to significant weight loss with potentially less muscle loss and fewer side effects. People are already hunting for gray/black market versions. Early trial data on Retatrutide showed participants losing up to 24% of their body weight over 48 weeks, with notably better muscle preservation compared to earlier GLP-1 drugs when combined with resistance training. These next-generation drugs are becoming more targeted, but access, safety, and proper use remain key issues. This conversation made the rapid evolution of these drugs feel very real. It’s wild how fast this space is moving. What’s your take on the new generation of GLP drugs like Retatrutide?

Camus

361,199 Aufrufe • vor 4 Monaten

“This is going to be a trillion-dollar drug.” Andrew D. Huberman, Ph.D. says retatrutide is the peptide that’s about to “change everything.” Currently in a Phase III clinical trial in humans, retatrutide caused up to one-third body weight loss in just six months, with some degree of muscle sparing. “The bodybuilding community has been onto this for a long time.” “Then it shows up in Hollywood. Everyone lies or avoids answering the question of how they got so jacked. They talk about eating chicken breasts, and they’re actually taking growth hormone, Winstrol, and retatrutide.” “We are looking at a potential change in the laws around peptides such that buying peptides would become illegal. I think this is a terrible idea, but the motivation behind this is largely because Eli Lilly owns the patent.” “Lilly would like to protect the domain over that patent. This is going to be a trillion-dollar drug.”
3:16

“This is going to be a trillion-dollar drug.” Andrew D. Huberman, Ph.D. says retatrutide is the peptide that’s about to “change everything.” Currently in a Phase III clinical trial in humans, retatrutide caused up to one-third body weight loss in just six months, with some degree of muscle sparing. “The bodybuilding community has been onto this for a long time.” “Then it shows up in Hollywood. Everyone lies or avoids answering the question of how they got so jacked. They talk about eating chicken breasts, and they’re actually taking growth hormone, Winstrol, and retatrutide.” “We are looking at a potential change in the laws around peptides such that buying peptides would become illegal. I think this is a terrible idea, but the motivation behind this is largely because Eli Lilly owns the patent.” “Lilly would like to protect the domain over that patent. This is going to be a trillion-dollar drug.”

TBPN

1,979,901 Aufrufe • vor 8 Monaten

$LLY $NVO $HIMS 🚨 ELI LILLY SUED THE FDA TO GET RETATRUTIDE RECLASSIFIED AS A 'BIOLOGIC' "THIS IS THE MOST IMPORTANT EVENT" IN GLP-1s RIGHT NOW Bijan Salehizadeh: "Many years ago, the FDA said the definition of what is a biologic in the peptide world is more than 40 amino acids. Retatrutide is 39. That's just the facts." "And then there are 2 "linker" amino acids that... look, I went to medical school. Those aren't amino acids! They're like other things that [the amino acids] link onto to give it longer biological life in your body." "Lilly is claiming those two other entities are actually amino acids. So they proactively sued the FDA, Lilly did, and said, 'Retatrutide needs to be defined as a biologic.'" "Now, why are they so aggressive on this? Because if it's a biologic, you get 13 years of market exclusivity [versus only 9 years for a normal drug]... plus the price of biologics are typically into the upper thousands of month." "The peak sales estimates for retatrutide are ten billion or more a year. Some people call it the first trillion-dollar drug." Oral arguments are Sep 24 in Chicago. Bijan says he expects a ruling 3-4 months later:
5:49

$LLY $NVO $HIMS 🚨 ELI LILLY SUED THE FDA TO GET RETATRUTIDE RECLASSIFIED AS A 'BIOLOGIC' "THIS IS THE MOST IMPORTANT EVENT" IN GLP-1s RIGHT NOW Bijan Salehizadeh: "Many years ago, the FDA said the definition of what is a biologic in the peptide world is more than 40 amino acids. Retatrutide is 39. That's just the facts." "And then there are 2 "linker" amino acids that... look, I went to medical school. Those aren't amino acids! They're like other things that [the amino acids] link onto to give it longer biological life in your body." "Lilly is claiming those two other entities are actually amino acids. So they proactively sued the FDA, Lilly did, and said, 'Retatrutide needs to be defined as a biologic.'" "Now, why are they so aggressive on this? Because if it's a biologic, you get 13 years of market exclusivity [versus only 9 years for a normal drug]... plus the price of biologics are typically into the upper thousands of month." "The peak sales estimates for retatrutide are ten billion or more a year. Some people call it the first trillion-dollar drug." Oral arguments are Sep 24 in Chicago. Bijan says he expects a ruling 3-4 months later:

Hims House

25,432 Aufrufe • vor 1 Monat

BPC-157 causing cancer? FDA shutting down peptide trials? “No human RCTs have ever been done on peptides?” In this video, Dr. Alex Tatem — board-certified urologist and fellowship-trained men’s health specialist — reacts to viral claims made on Shawn Ryan Show about BPC-157, TB-500, peptides, angiogenesis, cancer risk, and peptide safety. We break down: • Whether BPC-157 actually causes cancer • The truth about angiogenesis and tumor growth • FDA regulation of peptides and compounding • Why the “no randomized controlled trials” claim is completely false • Human clinical trial data on peptides • The real history of BPC-157 clinical studies • Huberman’s correction of viral peptide misinformation • Why peptide fearmongering could push patients toward unsafe gray-market sourcing This is not bro-science or influencer hype. This is a deep dive into the actual published literature, peptide pharmacology, FDA policy, and performance medicine. Topics covered include: BPC-157, TB-500, peptides, angiogenesis, cancer biology, GLP-1 drugs, Ozempic, tirzepatide, semaglutide, TRT, peptide therapy, biohacking, longevity, anti-aging medicine, compounding pharmacies, peptide legality, Andrew D. Huberman, Ph.D. , Shawn Ryan Show, FDA peptide regulation, growth hormone history, and performance medicine. If you’ve ever wondered whether BPC-157 is dangerous, whether peptides are legal, or whether the internet is fearmongering about peptide therapy — this video is for you.
20:43

BPC-157 causing cancer? FDA shutting down peptide trials? “No human RCTs have ever been done on peptides?” In this video, Dr. Alex Tatem — board-certified urologist and fellowship-trained men’s health specialist — reacts to viral claims made on Shawn Ryan Show about BPC-157, TB-500, peptides, angiogenesis, cancer risk, and peptide safety. We break down: • Whether BPC-157 actually causes cancer • The truth about angiogenesis and tumor growth • FDA regulation of peptides and compounding • Why the “no randomized controlled trials” claim is completely false • Human clinical trial data on peptides • The real history of BPC-157 clinical studies • Huberman’s correction of viral peptide misinformation • Why peptide fearmongering could push patients toward unsafe gray-market sourcing This is not bro-science or influencer hype. This is a deep dive into the actual published literature, peptide pharmacology, FDA policy, and performance medicine. Topics covered include: BPC-157, TB-500, peptides, angiogenesis, cancer biology, GLP-1 drugs, Ozempic, tirzepatide, semaglutide, TRT, peptide therapy, biohacking, longevity, anti-aging medicine, compounding pharmacies, peptide legality, Andrew D. Huberman, Ph.D. , Shawn Ryan Show, FDA peptide regulation, growth hormone history, and performance medicine. If you’ve ever wondered whether BPC-157 is dangerous, whether peptides are legal, or whether the internet is fearmongering about peptide therapy — this video is for you.

Dr. Alex Tatem

78,089 Aufrufe • vor 5 Monaten

today, we're announcing our most long-awaited offering – Superpower Peptides. 1 in 5 Americans have already tried a GLP1, but the wave is only beginning. for too long, people seeking access to new peptides have been left with two options: go without, or turn to unregulated sources that put their health at risk. that's beginning to change. and we've been building. introducing Superpower Peptides: • Pure. Third-party tested. • Rigorously sourced • Backed by science as the FDA moves to restore regulated access to 12 key peptides (like BPC 157), we are ready. existing members get early access today. peptides will be one of the biggest revolutions in human health and one of the fastest growing consumer markets next to AI. you can reserve your username on our waitlist here: 👉 superpower . com / peptides __ peptides, by Superpower. a new era of health is coming.
0:25

today, we're announcing our most long-awaited offering – Superpower Peptides. 1 in 5 Americans have already tried a GLP1, but the wave is only beginning. for too long, people seeking access to new peptides have been left with two options: go without, or turn to unregulated sources that put their health at risk. that's beginning to change. and we've been building. introducing Superpower Peptides: • Pure. Third-party tested. • Rigorously sourced • Backed by science as the FDA moves to restore regulated access to 12 key peptides (like BPC 157), we are ready. existing members get early access today. peptides will be one of the biggest revolutions in human health and one of the fastest growing consumer markets next to AI. you can reserve your username on our waitlist here: 👉 superpower . com / peptides __ peptides, by Superpower. a new era of health is coming.

jacob peters

11,001 Aufrufe • vor 5 Monaten

🚨 “EVERYONE WILL BE ON THIS” — TOP PLASTIC SURGEON CALLS RETATRUTIDE THE GREATEST DRUG EVER CREATED A viral interview featuring Dr. Terry Dubrow is exploding after he made a claim that’s catching serious attention: Retatrutide, a new drug from Eli Lilly and Company, could be the most powerful peptide we’ve ever seen. And according to him, it’s already spreading before approval. • Completed all 3 clinical trial phases (not FDA approved yet) • Expected approval timeline: potentially within months • Triple-hormone mechanism (fat loss + muscle preservation + appetite control) • Being called the next evolution of GLP-1 drugs He claims compounding pharmacies are already making versions of it. Meaning people are taking it right now, without regulation. • “Everyone’s on it” - especially in gym circles • No oversight on sourcing, purity, or dosing • Unknown additives, contamination risks, or long-term effects • No clarity on where it’s being manufactured And yet the hype is exploding: • Being labeled a potential trillion-dollar drug • Said to outperform current weight-loss injections • Designed to burn fat while preserving muscle, something older drugs struggled with But it doesn’t stop at weight loss. According to Dr. Dubrow, drugs in this category are being explored or used for: • Alzheimer’s • Heart disease (already approved in some cases) • Arthritis • Addiction (including alcohol dependence) • Schizophrenia • Early-stage cancer research (tumor growth slowdown) The logic? It all comes back to blood sugar control, inflammation, and metabolic health. Systems tied to nearly every major disease. Which leads to the bigger claim: That in the near future… people won’t just take these drugs to lose weight. They’ll take them to live longer. But here’s the part no one can answer yet: If millions are already using unregulated versions… what exactly are they putting into their bodies? Is this the biggest medical breakthrough of the decade... or a mass rollout happening before anyone’s ready? 📹: YouTube/truehustlepodcast
5:47

🚨 “EVERYONE WILL BE ON THIS” — TOP PLASTIC SURGEON CALLS RETATRUTIDE THE GREATEST DRUG EVER CREATED A viral interview featuring Dr. Terry Dubrow is exploding after he made a claim that’s catching serious attention: Retatrutide, a new drug from Eli Lilly and Company, could be the most powerful peptide we’ve ever seen. And according to him, it’s already spreading before approval. • Completed all 3 clinical trial phases (not FDA approved yet) • Expected approval timeline: potentially within months • Triple-hormone mechanism (fat loss + muscle preservation + appetite control) • Being called the next evolution of GLP-1 drugs He claims compounding pharmacies are already making versions of it. Meaning people are taking it right now, without regulation. • “Everyone’s on it” - especially in gym circles • No oversight on sourcing, purity, or dosing • Unknown additives, contamination risks, or long-term effects • No clarity on where it’s being manufactured And yet the hype is exploding: • Being labeled a potential trillion-dollar drug • Said to outperform current weight-loss injections • Designed to burn fat while preserving muscle, something older drugs struggled with But it doesn’t stop at weight loss. According to Dr. Dubrow, drugs in this category are being explored or used for: • Alzheimer’s • Heart disease (already approved in some cases) • Arthritis • Addiction (including alcohol dependence) • Schizophrenia • Early-stage cancer research (tumor growth slowdown) The logic? It all comes back to blood sugar control, inflammation, and metabolic health. Systems tied to nearly every major disease. Which leads to the bigger claim: That in the near future… people won’t just take these drugs to lose weight. They’ll take them to live longer. But here’s the part no one can answer yet: If millions are already using unregulated versions… what exactly are they putting into their bodies? Is this the biggest medical breakthrough of the decade... or a mass rollout happening before anyone’s ready? 📹: YouTube/truehustlepodcast

HustleBitch

672,833 Aufrufe • vor 5 Monaten

There's a question that keeps coming up: is retatrutide better than tirzepatide? In my experience, this is the wrong question. It's like asking whether steak or chicken is better. Steak is arguably more nutrient-dense, but some people do better on chicken, and there's no reason you wouldn't vary your protein sources. It's the same with GLPs. It's not either/or, you have to experiment. > Tirzepatide is a dual agonist. It hits GLP-1 and GIP receptors. > Retatrutide is a triple agonist. It hits GLP-1, GIP, and glucagon receptors. That glucagon piece is the key difference. It changes how your body uses fuel in a way tirzepatide simply doesn't. In clinical trials, retatrutide produced 24% average weight loss in 48 weeks. Tirzepatide produced 21% in 72 weeks. Reta produced better results in almost half the time. The glucagon receptor drives thermogenesis and fat oxidation, which you don't get with a dual agonist. But retatrutide comes with a tradeoff. It raises resting heart rate by 5-10 BPM, driven by the glucagon receptor, and happens at every dose level. Reta peaks around week 24 and reverses when you stop. This doesn't happen with tirzepatide. And that's exactly why you shouldn't be on either of these indefinitely. The problem is that most people are scared to cycle off because they've heard the horror stories about weight rebound. As a result, they stay on way too long. This isn't medical advice, but I believe the right approach is to be 12-16 weeks on, 8-10 weeks off. You cycle, monitor, and adjust. If you don't know how to properly come off a GLP, you have no business being on one. On top of that, if you're running the experiment but not tracking it, you're wasting it. - Get labs done: fasting insulin, blood glucose, A1C, etc. - Wear a tracker: monitor heart rate and HRV These compounds impact metabolic markers that matter way more than bodyweight. If you have weight to lose and you're interested in GLPs, run at least one cycle of each. See how your body responds to retatrutide. Then see how it responds to tirzepatide. Compare the data, and that's how you'll find what works. Because in performance healthcare, data wins, not the math. Comment "FATLOSS" below, and I'll send you my 70-page Peptide Bible. P.S. None of this is medical advice nor a recommendation.
1:09

There's a question that keeps coming up: is retatrutide better than tirzepatide? In my experience, this is the wrong question. It's like asking whether steak or chicken is better. Steak is arguably more nutrient-dense, but some people do better on chicken, and there's no reason you wouldn't vary your protein sources. It's the same with GLPs. It's not either/or, you have to experiment. > Tirzepatide is a dual agonist. It hits GLP-1 and GIP receptors. > Retatrutide is a triple agonist. It hits GLP-1, GIP, and glucagon receptors. That glucagon piece is the key difference. It changes how your body uses fuel in a way tirzepatide simply doesn't. In clinical trials, retatrutide produced 24% average weight loss in 48 weeks. Tirzepatide produced 21% in 72 weeks. Reta produced better results in almost half the time. The glucagon receptor drives thermogenesis and fat oxidation, which you don't get with a dual agonist. But retatrutide comes with a tradeoff. It raises resting heart rate by 5-10 BPM, driven by the glucagon receptor, and happens at every dose level. Reta peaks around week 24 and reverses when you stop. This doesn't happen with tirzepatide. And that's exactly why you shouldn't be on either of these indefinitely. The problem is that most people are scared to cycle off because they've heard the horror stories about weight rebound. As a result, they stay on way too long. This isn't medical advice, but I believe the right approach is to be 12-16 weeks on, 8-10 weeks off. You cycle, monitor, and adjust. If you don't know how to properly come off a GLP, you have no business being on one. On top of that, if you're running the experiment but not tracking it, you're wasting it. - Get labs done: fasting insulin, blood glucose, A1C, etc. - Wear a tracker: monitor heart rate and HRV These compounds impact metabolic markers that matter way more than bodyweight. If you have weight to lose and you're interested in GLPs, run at least one cycle of each. See how your body responds to retatrutide. Then see how it responds to tirzepatide. Compare the data, and that's how you'll find what works. Because in performance healthcare, data wins, not the math. Comment "FATLOSS" below, and I'll send you my 70-page Peptide Bible. P.S. None of this is medical advice nor a recommendation.

Michael Morelli

39,921 Aufrufe • vor 5 Monaten

RETATRUTIDE is NOT JUST for WEIGHT LOSS… …and the fact that that’s what everyone is obsessing over tells me we’re still missing the point. 🙃 Because what I’m looking at? It’s not just the scale. It’s what’s happening underneath it. We’re talking 24% body weight reduction in trials… sure. BUT ALSO: 47% drop in inflammatory markers in 12 weeks. 2.1% drop in HbA1c. 42% reduction in visceral fat (the dangerous kind hugging your organs). 🫁 And then it gets uncomfortable… 31% lower cardiovascular mortality. 28% fewer heart attacks. 22% fewer strokes. Like… pause there. Because if this was just about weight loss… those numbers wouldn’t exist. This is metabolism. This is inflammation. This is mitochondrial signaling. 🧬 And THIS is where I start side-eyeing the narrative. Because you’ve been told this is about “calories” and “willpower.” Meanwhile your body is sitting there like— “Hey… I’m inflamed. I’m insulin resistant. I’m storing for a reason.” 👀 And instead of asking why… We’ve been handed drugs and told to shrink. But here’s the part nobody’s talking about… What happens when you stop? With semaglutide (Ozempic)… about 72% of people regain the weight. Tirzepatide? Around 60%. Retatrutide? ONLY 5–10%. That’s not a small difference. That’s a completely different conversation. Because now we’re NOT just talking about weight suppression… We’re talking about whether the terrain (esp hormones and body talk) actually changed. And if you’ve ever felt like you’re doing everything right… but your body keeps pulling you back… this matters more than you think. Because your body isn’t trying to sabotage you. It’s responding to something deeper. If you want me to break down what this actually means… and how peptides are shifting the entire conversation— Comment PEPTIDES and I’ll send you the full breakdown. 💡 #peptides #biohacking #womenshealth #hormones #healthandwellbeing
1:15

RETATRUTIDE is NOT JUST for WEIGHT LOSS… …and the fact that that’s what everyone is obsessing over tells me we’re still missing the point. 🙃 Because what I’m looking at? It’s not just the scale. It’s what’s happening underneath it. We’re talking 24% body weight reduction in trials… sure. BUT ALSO: 47% drop in inflammatory markers in 12 weeks. 2.1% drop in HbA1c. 42% reduction in visceral fat (the dangerous kind hugging your organs). 🫁 And then it gets uncomfortable… 31% lower cardiovascular mortality. 28% fewer heart attacks. 22% fewer strokes. Like… pause there. Because if this was just about weight loss… those numbers wouldn’t exist. This is metabolism. This is inflammation. This is mitochondrial signaling. 🧬 And THIS is where I start side-eyeing the narrative. Because you’ve been told this is about “calories” and “willpower.” Meanwhile your body is sitting there like— “Hey… I’m inflamed. I’m insulin resistant. I’m storing for a reason.” 👀 And instead of asking why… We’ve been handed drugs and told to shrink. But here’s the part nobody’s talking about… What happens when you stop? With semaglutide (Ozempic)… about 72% of people regain the weight. Tirzepatide? Around 60%. Retatrutide? ONLY 5–10%. That’s not a small difference. That’s a completely different conversation. Because now we’re NOT just talking about weight suppression… We’re talking about whether the terrain (esp hormones and body talk) actually changed. And if you’ve ever felt like you’re doing everything right… but your body keeps pulling you back… this matters more than you think. Because your body isn’t trying to sabotage you. It’s responding to something deeper. If you want me to break down what this actually means… and how peptides are shifting the entire conversation— Comment PEPTIDES and I’ll send you the full breakdown. 💡 #peptides #biohacking #womenshealth #hormones #healthandwellbeing

Dr Diane Kazer

78,604 Aufrufe • vor 5 Monaten

BPC-157 and TB-500 are two of the most talked-about peptides in fitness, bodybuilding, and biohacking. Together they’re often called the “Wolverine Stack” — a peptide combination rumored to dramatically accelerate healing of tendons, ligaments, muscles, and injuries. But do BPC-157 and TB-500 actually work in humans, or is the Wolverine Stack just another example of internet bro-science? In this evidence-based deep dive, Dr. Alex Tatem (board-certified urologist and men’s health specialist) breaks down the real science behind BPC-157 and TB-500 — including their biochemical mechanisms, animal research, potential healing effects, safety concerns, and why pharmaceutical companies have never brought these peptides through full FDA clinical trials. We explore the nitric oxide signaling, angiogenesis, VEGF pathways, actin regulation, and tissue repair biology behind these compounds and explain why rodent studies look promising — but why human clinical evidence is still extremely limited. You’ll also learn about: • What BPC-157 (Body Protection Compound-157) actually is • TB-500 vs Thymosin Beta-4 explained • The origin of the Wolverine Stack peptide protocol • Peptides for tendon healing and ligament injuries • BPC-157 for gut healing and musculoskeletal repair • TB-500 and actin-mediated tissue regeneration • Why most peptide research comes from one Croatian research group • The patent law problem preventing pharmaceutical development • Real risks of grey-market peptide contamination • Why WADA bans BPC-157 and TB-500 in competitive athletes • Theoretical cancer risks related to angiogenesis • What the current scientific literature actually shows If you've ever searched: “Does BPC-157 work?” “What is TB-500?” “Peptides for healing injuries” “BPC-157 tendon repair” “Wolverine Stack peptides explained” — this video breaks down the science. The peptides may be promising. But promise and proof are not the same thing. Drop a comment below: Have you ever used BPC-157, TB-500, or other peptides? What was your experience? 👍 Like the video if you want more evidence-based breakdowns of supplements, PEDs, and peptides. Subscribe for deep dives on testosterone, steroids, peptides, supplements, and men’s health science.
30:26

BPC-157 and TB-500 are two of the most talked-about peptides in fitness, bodybuilding, and biohacking. Together they’re often called the “Wolverine Stack” — a peptide combination rumored to dramatically accelerate healing of tendons, ligaments, muscles, and injuries. But do BPC-157 and TB-500 actually work in humans, or is the Wolverine Stack just another example of internet bro-science? In this evidence-based deep dive, Dr. Alex Tatem (board-certified urologist and men’s health specialist) breaks down the real science behind BPC-157 and TB-500 — including their biochemical mechanisms, animal research, potential healing effects, safety concerns, and why pharmaceutical companies have never brought these peptides through full FDA clinical trials. We explore the nitric oxide signaling, angiogenesis, VEGF pathways, actin regulation, and tissue repair biology behind these compounds and explain why rodent studies look promising — but why human clinical evidence is still extremely limited. You’ll also learn about: • What BPC-157 (Body Protection Compound-157) actually is • TB-500 vs Thymosin Beta-4 explained • The origin of the Wolverine Stack peptide protocol • Peptides for tendon healing and ligament injuries • BPC-157 for gut healing and musculoskeletal repair • TB-500 and actin-mediated tissue regeneration • Why most peptide research comes from one Croatian research group • The patent law problem preventing pharmaceutical development • Real risks of grey-market peptide contamination • Why WADA bans BPC-157 and TB-500 in competitive athletes • Theoretical cancer risks related to angiogenesis • What the current scientific literature actually shows If you've ever searched: “Does BPC-157 work?” “What is TB-500?” “Peptides for healing injuries” “BPC-157 tendon repair” “Wolverine Stack peptides explained” — this video breaks down the science. The peptides may be promising. But promise and proof are not the same thing. Drop a comment below: Have you ever used BPC-157, TB-500, or other peptides? What was your experience? 👍 Like the video if you want more evidence-based breakdowns of supplements, PEDs, and peptides. Subscribe for deep dives on testosterone, steroids, peptides, supplements, and men’s health science.

Dr. Alex Tatem

22,765 Aufrufe • vor 7 Monaten

RFK Jr. is declaring an end to the FDA's "war on alternative medicine." He argues that the agency has overstepped its role, shifting from a body that provides scientific guidance to one that restricts medical freedom. Why is there a war on healing substances like stem cells, peptides, vitamins, and minerals? His solution? The FDA should do the science and inform the public, but stop acting as a gatekeeper that denies Americans and their doctors the right to choose these treatments. He points to a shocking statistic: pharmaceutical drugs are the third leading cause of death in the U.S. With this as the status quo, he questions why safe, natural alternatives are so heavily restricted. His powerful conclusion? It's time to trust the intelligence and intuition of the American people to make their own health choices, rather than leaving our well-being solely in the hands of Big Pharma.
2:28

RFK Jr. is declaring an end to the FDA's "war on alternative medicine." He argues that the agency has overstepped its role, shifting from a body that provides scientific guidance to one that restricts medical freedom. Why is there a war on healing substances like stem cells, peptides, vitamins, and minerals? His solution? The FDA should do the science and inform the public, but stop acting as a gatekeeper that denies Americans and their doctors the right to choose these treatments. He points to a shocking statistic: pharmaceutical drugs are the third leading cause of death in the U.S. With this as the status quo, he questions why safe, natural alternatives are so heavily restricted. His powerful conclusion? It's time to trust the intelligence and intuition of the American people to make their own health choices, rather than leaving our well-being solely in the hands of Big Pharma.

Camus

197,927 Aufrufe • vor 1 Jahr

Do you consider the bobsled body type to he attractive? In hopes of getting a better body, many have been turning to fake GLP-1 drugs to try to lose weight. Not a smart idea! Many of the copycat drug companies are now being referred to the DOJ for investigation over alleged violations of federal drug laws 👀 This is what happens when they put speed and profit over patient safety. So many advertisements tricking men and women alike into potentially harming their own health. The FDA needs to look beyond Hims and consider the broader landscape, including Ro, Willow, and others, all of which are engaging in what appear to be very unsafe practices. Don’t let them get away with it!
0:32

Do you consider the bobsled body type to he attractive? In hopes of getting a better body, many have been turning to fake GLP-1 drugs to try to lose weight. Not a smart idea! Many of the copycat drug companies are now being referred to the DOJ for investigation over alleged violations of federal drug laws 👀 This is what happens when they put speed and profit over patient safety. So many advertisements tricking men and women alike into potentially harming their own health. The FDA needs to look beyond Hims and consider the broader landscape, including Ro, Willow, and others, all of which are engaging in what appear to be very unsafe practices. Don’t let them get away with it!

Matt Wallace

1,407,363 Aufrufe • vor 8 Monaten

Alex Karnal (Alex Karnal) is the most talented bio and healthcare investor I've ever met. He's spent 20 years in the industry and says 2025 was the single most exciting year he's seen. The start of a once-in-a-lifetime, trillion-dollar revolution in public health. He explains how few people realize we already have the medicines to prevent our deadliest diseases. The problem is that almost no one takes them. There's a population of people born with a mutation that means their bodies don't produce a protein called PCSK9. Their lifetime risk of cardiovascular disease is 88% lower than yours. Pharma turned that genetic advantage into a drug. It's been approved for years, but the number of people taking it is still vanishingly small. Partly because high cholesterol is a silent killer. You feel nothing, right up until you have a heart attack. And partly because the health system makes it punishingly hard to stay on a preventive drug like a PCSK9 inhibitor. In other words, the medicine works, but the system around it doesn't. That's what's starting to change, and in this episode, Alex explains why. We discuss the "health stack" he believes can add a decade to most lives, why oral GLP-1s are breaking every adoption record in pharma, peptides and citizen pharmacology, and what AI is doing to drug discovery. I wish I had an "Alex" for every interesting topic. We've been having versions of this conversation for over five years, and every single one is as clear and as useful as this one. Enjoy! Timestamps: 0:00 Intro 1:00 The State of Modern Medicine 5:00 Designing the Modern Health Stack 12:17 The GLP-1 Inflection Point 19:18 The Biological Mechanisms of GLP-1 30:36 Overcoming Frictions in Healthcare 34:19 Cardiovascular Disease 44:04 Addressing Alzheimer's 47:04 The Future of Cancer 57:33 Drug Discovery 1:05:25 AI and Scientific Super Intelligence 1:14:40 Citizen Pharmacology and the Peptide Movement 1:18:13 Background and Career Journey 1:31:09 Braidwell's Investment Approach 1:33:30 The Kindest Thing
1:38:17

Alex Karnal (Alex Karnal) is the most talented bio and healthcare investor I've ever met. He's spent 20 years in the industry and says 2025 was the single most exciting year he's seen. The start of a once-in-a-lifetime, trillion-dollar revolution in public health. He explains how few people realize we already have the medicines to prevent our deadliest diseases. The problem is that almost no one takes them. There's a population of people born with a mutation that means their bodies don't produce a protein called PCSK9. Their lifetime risk of cardiovascular disease is 88% lower than yours. Pharma turned that genetic advantage into a drug. It's been approved for years, but the number of people taking it is still vanishingly small. Partly because high cholesterol is a silent killer. You feel nothing, right up until you have a heart attack. And partly because the health system makes it punishingly hard to stay on a preventive drug like a PCSK9 inhibitor. In other words, the medicine works, but the system around it doesn't. That's what's starting to change, and in this episode, Alex explains why. We discuss the "health stack" he believes can add a decade to most lives, why oral GLP-1s are breaking every adoption record in pharma, peptides and citizen pharmacology, and what AI is doing to drug discovery. I wish I had an "Alex" for every interesting topic. We've been having versions of this conversation for over five years, and every single one is as clear and as useful as this one. Enjoy! Timestamps: 0:00 Intro 1:00 The State of Modern Medicine 5:00 Designing the Modern Health Stack 12:17 The GLP-1 Inflection Point 19:18 The Biological Mechanisms of GLP-1 30:36 Overcoming Frictions in Healthcare 34:19 Cardiovascular Disease 44:04 Addressing Alzheimer's 47:04 The Future of Cancer 57:33 Drug Discovery 1:05:25 AI and Scientific Super Intelligence 1:14:40 Citizen Pharmacology and the Peptide Movement 1:18:13 Background and Career Journey 1:31:09 Braidwell's Investment Approach 1:33:30 The Kindest Thing

Patrick OShaughnessy

679,452 Aufrufe • vor 5 Monaten

In our recent broadcast Nathan Goodyear, MD, MD(H) said something that really resonated with me. He said that somewhere in the process of drug development, we've lost the humanity of the patient and the potential of what it means to be a physician to serve the patient. He's right. And I've seen it firsthand for a long time now. Technology and clinical innovation are moving faster than ever, but the regulatory process hasn't kept pace. Patients have access to more information than at any point in history, yet they can't access treatments that could help them because the approval pipeline is still functioning decades behind the science. At Williams Cancer Institute , we've lived this challenge. Cancer is complex. It often requires multiple drugs working together. But the FDA has traditionally required single-drug approval, which means a drug that may not show strong results on its own, but could be transformative in combination, never gets its chance. We've been working to change that. We now have a four-drug combination in clinical trials, and the FDA is beginning to open up to combination approaches. But it's been a long road. Dr. Goodyear put it well: we need to innovate on the regulatory side to match the innovation happening on the clinical side. How do we get treatments to patients faster while maintaining safety? Because the cost of a life can't be measured in dollars, timelines, or quarterly earnings. It's measured in relationships, in time with family, in the chance to keep living.
1:32

In our recent broadcast Nathan Goodyear, MD, MD(H) said something that really resonated with me. He said that somewhere in the process of drug development, we've lost the humanity of the patient and the potential of what it means to be a physician to serve the patient. He's right. And I've seen it firsthand for a long time now. Technology and clinical innovation are moving faster than ever, but the regulatory process hasn't kept pace. Patients have access to more information than at any point in history, yet they can't access treatments that could help them because the approval pipeline is still functioning decades behind the science. At Williams Cancer Institute , we've lived this challenge. Cancer is complex. It often requires multiple drugs working together. But the FDA has traditionally required single-drug approval, which means a drug that may not show strong results on its own, but could be transformative in combination, never gets its chance. We've been working to change that. We now have a four-drug combination in clinical trials, and the FDA is beginning to open up to combination approaches. But it's been a long road. Dr. Goodyear put it well: we need to innovate on the regulatory side to match the innovation happening on the clinical side. How do we get treatments to patients faster while maintaining safety? Because the cost of a life can't be measured in dollars, timelines, or quarterly earnings. It's measured in relationships, in time with family, in the chance to keep living.

Jason R. Williams, MD, DABR

21,307 Aufrufe • vor 7 Monaten

"Can you say to me right now, that amount of mercury being injected into a baby will not hurt it?" William Egan, the FDA director, couldn't answer a single question about thimerosal definitively with science or specificity. Every response was without substance, behaving as a cagey lawyer trying to avoid saying something incriminating, protecting his criminal corporate masters that fund half of his agency and control it. The only safety study on thimerosal done in humans at the time, was done by the corporation Eli Lily back in 1929. What's even crazier, is that they only tested it 27 people who were already dying from meningitis, and every single one of them died in the trial. They didn't attribute the fatalities to the thimerosal of course, so that allowed them to add it to a bunch of vaccines without question. This is the kind of science the FDA required before allowing a vaccine containing mercury to be injected into your infant. It's criminal negligence. If you still trust the FDA/CDC and pharma when they say vaccines don't cause autism, you are dangerously delusional and have terrible discernment.
2:38

"Can you say to me right now, that amount of mercury being injected into a baby will not hurt it?" William Egan, the FDA director, couldn't answer a single question about thimerosal definitively with science or specificity. Every response was without substance, behaving as a cagey lawyer trying to avoid saying something incriminating, protecting his criminal corporate masters that fund half of his agency and control it. The only safety study on thimerosal done in humans at the time, was done by the corporation Eli Lily back in 1929. What's even crazier, is that they only tested it 27 people who were already dying from meningitis, and every single one of them died in the trial. They didn't attribute the fatalities to the thimerosal of course, so that allowed them to add it to a bunch of vaccines without question. This is the kind of science the FDA required before allowing a vaccine containing mercury to be injected into your infant. It's criminal negligence. If you still trust the FDA/CDC and pharma when they say vaccines don't cause autism, you are dangerously delusional and have terrible discernment.

Inversionism

258,823 Aufrufe • vor 3 Jahren

$IBRX oh my god, PLEASE you gotta watch this: On the Cuomo show last night with Dr. Pat Soon-Shiong as a guest, an ex-FDA exec basically spilled everything: Total CONFIRMATION of the CHAOTIC MESS INSIDE the FDA and how deep BIG PHARMA’S INFLUENCE really runs. Uncoordinated and bureaucratic is still an understatement — it’s practically by design at this point. And then there’s the bit about Merck and why Keytruda got approved… fascinating, if not a little too telling: “Multibillion dollar company with floors of people that understand the science in very subtle ways and what the most direct streamline path will be to get an FDA novel.” Admittedly there’s supposedly a new way of thinking now within the FDA - the talk of “collaboration,” “accelerated approvals,” etc. But, also, in this round it’s confirmed: real change will still take a while. Meanwhile, patients are still running out of time - this program made that painfully clear (see tweets of patients reports)
2:02

$IBRX oh my god, PLEASE you gotta watch this: On the Cuomo show last night with Dr. Pat Soon-Shiong as a guest, an ex-FDA exec basically spilled everything: Total CONFIRMATION of the CHAOTIC MESS INSIDE the FDA and how deep BIG PHARMA’S INFLUENCE really runs. Uncoordinated and bureaucratic is still an understatement — it’s practically by design at this point. And then there’s the bit about Merck and why Keytruda got approved… fascinating, if not a little too telling: “Multibillion dollar company with floors of people that understand the science in very subtle ways and what the most direct streamline path will be to get an FDA novel.” Admittedly there’s supposedly a new way of thinking now within the FDA - the talk of “collaboration,” “accelerated approvals,” etc. But, also, in this round it’s confirmed: real change will still take a while. Meanwhile, patients are still running out of time - this program made that painfully clear (see tweets of patients reports)

Berlinergy

25,734 Aufrufe • vor 7 Monaten

He sold his soul to Big Pharma and they fired him anyways. 🤦‍♂️ Vinay Prasad Vinay Prasad MD MPH is one of the many reasons MAHA is in deep trouble...and he really is a cautionary tale. He was wrong about Ivermectin for COVID-19 and he was even more wrong about Ivermectin, Mebendazole and Fenbendazole in Cancer. But he was "Big Pharma" and "TV" friendly, so MAHA backed his hiring into the FDA, where he took on several important roles. This is what happens when you replace a real movement, with actors. The strategy of trying to meet Big Pharma halfway on corruption and fraud, by hiring people who are only "mildly corrupted" and still love Big Pharma, is a poor one, because it's very transparent. Vinay's arguments about repurposed drugs are so painfully idiotic, that I can't fathom how he can hold on to his medical license as an Oncologist, let alone be shoved in front of millions of Americans at the FDA. "It's not plausible anti-parasitics work for cancer" except Johns Hopkins was granted a PATENT on Mebendazole for use in Glioblastoma, one of the most aggressive cancers and ran two Clinical Trials including in CHILDREN. If it's "not plausible" and "we looked in the 1970s and didn't see anything", why would one of America's largest Cancer Centers spend 5 years getting a PATENT on it as well as two Clinical Trials AND put children with Brain Cancer at risk? Is Vinay really trying to tell us Johns Hopkins applied for grant funding and committed its resources to study "fringe" things that are "not plausible"? Meanwhile: - Fenbendazole Cancer Support Group on Facebook grew to over 100,000 before it was taken down - In late 2025, Florida Governor Ron Desantis committed over $60 million for Ivermectin in Cancer research via the Florida Cancer Innovation Fund - In early 2026, National Cancer Institute committed to studying Ivermectin in Cancer. Not bad for something that's "not plausible". And for all that, Vinay Prasad got kicked out of the FDA anyways. Vinay is not a stupid man, but he made a choice. "I have to bash Ivermectin" to position himself as a "moderate" and "Big Pharma friendly", and by doing so, he tore up his Hippocratic Oath (to further his career). Let's be honest, many doctors did the same during COVID-19 with the jabs. But they are pariahs on the fringe of society today. They are publicly ridiculed, mocked and no one trusts them anymore. Your average doctor has lower favorability rating than chlamydia and it's well earned. Many of these MAHA actors deserve the same fate. They sold out too. They just did it with a different flavor. The flavor of "Health Freedom".
1:26

He sold his soul to Big Pharma and they fired him anyways. 🤦‍♂️ Vinay Prasad Vinay Prasad MD MPH is one of the many reasons MAHA is in deep trouble...and he really is a cautionary tale. He was wrong about Ivermectin for COVID-19 and he was even more wrong about Ivermectin, Mebendazole and Fenbendazole in Cancer. But he was "Big Pharma" and "TV" friendly, so MAHA backed his hiring into the FDA, where he took on several important roles. This is what happens when you replace a real movement, with actors. The strategy of trying to meet Big Pharma halfway on corruption and fraud, by hiring people who are only "mildly corrupted" and still love Big Pharma, is a poor one, because it's very transparent. Vinay's arguments about repurposed drugs are so painfully idiotic, that I can't fathom how he can hold on to his medical license as an Oncologist, let alone be shoved in front of millions of Americans at the FDA. "It's not plausible anti-parasitics work for cancer" except Johns Hopkins was granted a PATENT on Mebendazole for use in Glioblastoma, one of the most aggressive cancers and ran two Clinical Trials including in CHILDREN. If it's "not plausible" and "we looked in the 1970s and didn't see anything", why would one of America's largest Cancer Centers spend 5 years getting a PATENT on it as well as two Clinical Trials AND put children with Brain Cancer at risk? Is Vinay really trying to tell us Johns Hopkins applied for grant funding and committed its resources to study "fringe" things that are "not plausible"? Meanwhile: - Fenbendazole Cancer Support Group on Facebook grew to over 100,000 before it was taken down - In late 2025, Florida Governor Ron Desantis committed over $60 million for Ivermectin in Cancer research via the Florida Cancer Innovation Fund - In early 2026, National Cancer Institute committed to studying Ivermectin in Cancer. Not bad for something that's "not plausible". And for all that, Vinay Prasad got kicked out of the FDA anyways. Vinay is not a stupid man, but he made a choice. "I have to bash Ivermectin" to position himself as a "moderate" and "Big Pharma friendly", and by doing so, he tore up his Hippocratic Oath (to further his career). Let's be honest, many doctors did the same during COVID-19 with the jabs. But they are pariahs on the fringe of society today. They are publicly ridiculed, mocked and no one trusts them anymore. Your average doctor has lower favorability rating than chlamydia and it's well earned. Many of these MAHA actors deserve the same fate. They sold out too. They just did it with a different flavor. The flavor of "Health Freedom".

William Makis

85,638 Aufrufe • vor 2 Monaten

YOU ALL GONNA BE EXCITED WITH THIS ONE, YOU CAN NOW GET A RELIABLE source of PEPTIDES FROM MYSELF FOLLOW SUPREME PEPTIDES AND WATCH THIS GROW, PEOPLE KNOW THEY CAN TRUST ME. BENEFITS BELOW ⬇️ Peptides are short chains of amino acids that act as signaling molecules in the body. Different peptides have very different effects, so the benefits depend entirely on which peptide you’re referring to. Here are some of the most commonly discussed peptide categories and their potential benefits: Healing and Recovery * BPC-157 – Often promoted for tendon, ligament, muscle, and gut healing. * TB-500 (Thymosin Beta-4 fragment) – May support tissue repair and reduce recovery time after injury. * Potential benefits: * Faster recovery from injuries * Improved wound healing * Reduced inflammation (evidence in humans is limited) Muscle Growth and Performance * CJC-1295 and Ipamorelin – Stimulate the body’s release of growth hormone. * Potential benefits: * Increased lean muscle mass * Better recovery after exercise * Improved sleep * Possible reduction in body fat Weight Loss * Tirzepatide and Semaglutide * Potential benefits: * Reduced appetite * Significant weight loss * Improved blood sugar control in people with diabetes Skin and Anti-Ageing * GHK-Cu (Copper Peptide) * Potential benefits: * Improved skin elasticity * Reduced appearance of fine lines * May promote hair growth * Supports wound healing Sexual Health * PT-141 (Bremelanotide) * Potential benefits: * Increased sexual desire in some people * Used for certain forms of low sexual desire Immune Function * Thymosin Alpha-1 * Potential benefits: * Supports immune system function * Studied in certain infections and cancers Are peptides safe? It depends on the peptide and how it’s used.
1:18

YOU ALL GONNA BE EXCITED WITH THIS ONE, YOU CAN NOW GET A RELIABLE source of PEPTIDES FROM MYSELF FOLLOW SUPREME PEPTIDES AND WATCH THIS GROW, PEOPLE KNOW THEY CAN TRUST ME. BENEFITS BELOW ⬇️ Peptides are short chains of amino acids that act as signaling molecules in the body. Different peptides have very different effects, so the benefits depend entirely on which peptide you’re referring to. Here are some of the most commonly discussed peptide categories and their potential benefits: Healing and Recovery * BPC-157 – Often promoted for tendon, ligament, muscle, and gut healing. * TB-500 (Thymosin Beta-4 fragment) – May support tissue repair and reduce recovery time after injury. * Potential benefits: * Faster recovery from injuries * Improved wound healing * Reduced inflammation (evidence in humans is limited) Muscle Growth and Performance * CJC-1295 and Ipamorelin – Stimulate the body’s release of growth hormone. * Potential benefits: * Increased lean muscle mass * Better recovery after exercise * Improved sleep * Possible reduction in body fat Weight Loss * Tirzepatide and Semaglutide * Potential benefits: * Reduced appetite * Significant weight loss * Improved blood sugar control in people with diabetes Skin and Anti-Ageing * GHK-Cu (Copper Peptide) * Potential benefits: * Improved skin elasticity * Reduced appearance of fine lines * May promote hair growth * Supports wound healing Sexual Health * PT-141 (Bremelanotide) * Potential benefits: * Increased sexual desire in some people * Used for certain forms of low sexual desire Immune Function * Thymosin Alpha-1 * Potential benefits: * Supports immune system function * Studied in certain infections and cancers Are peptides safe? It depends on the peptide and how it’s used.

Anthony Fowler

28,226 Aufrufe • vor 3 Monaten